A randomized double-blind, comparative study of ARN-509 plus androgen deprivation therapy (ADT) versus ADT alone in nonmetastatic castration-resistant prostate cancer (M0-CRPC): The SPARTAN trial.
2014 ◽
Vol 32
(15_suppl)
◽
pp. TPS5100-TPS5100
◽
2018 ◽
Vol 17
(2)
◽
pp. e1070-e1071
◽
2020 ◽
Vol 12
◽
pp. 175883592097813
2013 ◽
Vol 87
(2)
◽
pp. S175